Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B

Transplant Proc. 2007 Dec;39(10):3276-80. doi: 10.1016/j.transproceed.2007.07.085.

Abstract

Background: Orthotopic liver transplantation (OLT) is a viable treatment option for patients with hepatitis B (HBV) and concomitant hepatocellular carcinoma (HCC). However, cancer recurrence following transplantation approaches 20%. This study sought to identify the clinical and pathological factors associated with post-OLT survival.

Methods: Univariate and multivariate analyses considered the following variables: combination viral prophylaxis, HBV recurrence, tumor stage, vascular invasion, distribution, nodularity, pre- and post-OLT tumor size, pre-OLT alpha-fetoprotein (AFP), Milan and UCSF criteria, and Asian race.

Results: Cumulatively, HCC recurrence-free survival was 77%, 62%, and 53% at 1, 3, and 5 years, respectively, and was significantly better in patients who were free of viral recurrence post-OLT. Similarly, patients treated with combination prophylaxis had a significantly lower mortality than those who were not.

Conclusions: Multivariate analysis revealed that AFP>500 ng/mL, presence of vascular invasion by explant, HBV recurrence, and combination prophylaxis were independent predictors of HCC recurrence-free survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Antiviral Agents / therapeutic use*
  • Carcinoma, Hepatocellular / complications
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / surgery*
  • Disease-Free Survival
  • Hepatitis B / complications*
  • Hepatitis B / drug therapy
  • Hepatitis B / surgery
  • Humans
  • Immunoglobulins / therapeutic use
  • Lamivudine / therapeutic use
  • Liver Neoplasms / complications
  • Liver Neoplasms / mortality
  • Liver Neoplasms / surgery
  • Neoplasm Staging
  • Postoperative Complications / prevention & control
  • Postoperative Complications / virology
  • Recurrence
  • Retrospective Studies
  • Survival Analysis
  • Survivors
  • Time Factors
  • Virus Diseases / epidemiology
  • Virus Diseases / prevention & control*

Substances

  • Antiviral Agents
  • Immunoglobulins
  • Lamivudine
  • hepatitis B hyperimmune globulin